Option Care Health Inc (($OPCH)) has held its Q4 earnings call. Read on for the main highlights of the call. Option Care Health Inc. recently held ...

Simlandi and adalimumab-adaz have been with on formulary, along with Humira, beginning Jan. 1, 2025, Arpit Patel, Pharm.D., ...

Johnson & Johnson (NYSE: JNJ) has taken legal action against Samsung Bioepis, accusing the South Korean biotech of violating ...

Janssen has sued Samsung Bioepis, alleging it violated a settlement agreement by authorizing an unauthorized Stelara® ...

Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean ...

MedImpact Healthcare Systems, the nation’s largest independent provider of health solutions, technology, and pharmacy benefit ...

Both versions of Miller-Howard Income-Equity outperformed the Russell 1000 Value Index for the fourth quarter and for 2024.

Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...